Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Tuesday . The stock had previously closed at $27.60, but opened at $28.42. Ascentage Pharma Group International shares last traded at $29.26, with a volume of 2,005 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on AAPG shares. Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price on the stock. BTIG Research started coverage on Ascentage Pharma Group International in a research note on Monday, November 10th. They issued a “buy” rating and a $50.00 price target on the stock. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, November 24th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average price target of $48.50.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. The firm’s fifty day moving average price is $33.19 and its 200 day moving average price is $36.76.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the third quarter worth approximately $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International during the third quarter worth $204,000. Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International during the second quarter valued at about $227,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the third quarter worth about $383,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.